PPARγ agonist 17

• Description :

  PPARγ agonist 17 (Compound C1) is a PPARγ agonist. PPARγ agonist 17 enhances PPARγ activity and blocks the cell cycle in G2/M phase, inhibits cell migration and induces apoptosis in HT-29 cells. PPARγ agonist 17 has a broad spectrum anti-proliferative activity in cancer cells with relatively low toxicity in normal cells which cannot cross the blood-brain barrier[1].

• UNSPSC :

  12352005

• Target :

  PPAR

• Related Pathways :

  Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Smiles :

  C[C@]12[C@@](C(C=C3[C@]2(CC[C@@]4([C@@]3([H])C[C@](CC4)(C(O)=O)C)C)C)=O)([H])[C@@]5([C@@](C(C)([C@H](CC5)OC(CC6=CC=CC(NC(COC7=C(C)C=CC(C)=C7)=O)=C6)=O)C)([H])CC1)C

• Molecular Formula :

  C48H63NO7

• Molecular Weight :

  766.02

• References & Citations :

  [1]Lin H, et al. Design, synthesis and antitumor activity evaluation of novel modified 18β-glycyrrhetinate derivatives as PPARγ agonists. Bioorg Chem. 2025 Apr;157:108307.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [3054652-58-0]